Health and Healthcare
Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)
Published:
It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally you see a pattern. This month the only pattern seems to be one of no conviction either way. Here are the short seller reports in the short interest:
Stock (Ticker) NOV. 28 NOV. 14 CHANGE
Amgen Inc. (AMGN) 23,033,081 24,169,278 -4.70%
Celgene Corporation (CELG) 8,298,820 8,040,642 +3.21%
Biogen Idec Inc. (BIIB) 8,027,848 7,938,637 +1.12%
Genzyme Corporation (GENZ) 6,569,181 6,797,501 -3.36%
Gilead Sciences (GILD) 29,055,791 30,213,915 -3.83%
Jon C. Ogg
December 10, 2008
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.